Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

The need for rescue medications for breakthrough pain was also reduced, with around half of the patients on the drug needing none ... Pharma's non-opioid painkiller Journavx (suzetrigine), an ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It's the first new pharmaceutical approach to ...

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the ...

Eli Lilly biochemist David Wong (left) played an instrumental role in the discovery of Prozac. Source: Oregon State University, used with permission In the history of psychiatry, a few discoveries ...

In December, the U.S. Food and Drug Administration (FDA) approved a new treatment for people with insomnia, Dayvigo (lemborexant). The drug will be available in 5 or 10 milligram (mg) doses ...

The drug is thought to restore muscle regeneration, increase muscle mass, and reduce inflammation and scar tissue accumulation in boys with DMD, a progressive muscle-wasting disease that mostly ...